OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - MODERNA | Delayed Deutsche Boerse AG 14:30:45 12/06/2024 BST | ||
| 5.3 EUR | -0.93% |
|
| 1 month | -4.63% | ||
| 3 months | -3.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 12/06/24 | 5.3 | -0.93% |
| 11/06/24 | 5.35 | +0.38% |
| 10/06/24 | 5.33 | +0.76% |
| 07/06/24 | 5.29 | +1.15% |
| 06/06/24 | 5.23 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 12, 2024 at 02:30 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SF7QKE |
| ISIN | DE000SF7QKE4 |
| Date issued | 10/08/2021 |
| Strike | 723.5 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 2.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.25 € |
|---|---|
| Lowest since issue | 2.03 € |
| Spread | 0.01 € |
| Spread % | 0.19% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.4
USD
Average target price
144.4
USD
Spread / Average Target
-2.66%
- Stock Market
- Certificates
- Certificat
